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ABSTRACT 
Amavata, is a disease described in detail by Madhavakara in Madava Nidana. The word Amavata is 
made up of Ama and Vata. Aam is produced due to derangement of Jatharagni. This Aam then gets 
accumulated in Kostha, Sandhi and Trika with vitiated Vata and produce Stabdhata in body, 
swelling over joints and severe pain in multiple joints this condition is called Aamvata. This clinical 
feature of Aamvata is markedly similar to Rheumatoid Arthritis, which is a chronic autoimmune 
disease. Aim: To compare the efficacy of Erandaharitaki & Erandashunti as Abhyantarpana and 
Matrabasti in Aamvata. Materials & Methods: In the present study 80 patients (40 patients in 
each group) of Aamvata having aged between 20 to 65 years, fulfilling the inclusion criteria were 
selected from the OPD and IPD of Kayachikitsa Department of MGACH & RC, Salod (H), Wardha 
(Maharashtra). All patients were investigated for ESR and RA titre and were treated in two 
different groups with administration of Erandaharitaki in Group A and Eranda Sunthi in group B 
was given for Abhyantar Pana and Matrabasti. Results: After the treatment of 30 days, the 
improvement was observed in the symptoms of both the groups. The result of this treatment 
showed the improvement was better in Group A Abhyantarpana & Matrabasti with Erandaharitaki 
tailam in comparison to Group B Abhyantarpana & Matrabasti with Erandashunti tailam. 
Conclusion: The present study revealed the efficacy of Ayurveda therapy including both 
Abhyantarpana and Matrabasti for duration of 30 days in the management of Aamvata. 
KEYWORDS: Amavata, Erandaharitaki, Erandashunti, Matra Basti and Rheumatoid Arthritis. 
INTRODUCTION
Amavata is a commonest disorder of joint 
which spreading now a day. Aam is responsible for 
the formation of this disease which gets accumulated 
in joints leads to restriction in movement of joint 
with pain and tenderness. Aam is major factor for 
production of Aamvata[1]. The disease starts with 
minor symptoms but may develop and extend to all 
over the body wherever Ama is going to get lodged 
along with vitiated Vayu. As the disease progresses 
additional symptoms with complications like Khanj, 
Pangulya etc. may be seen. [2] 
This Aamvata is markedly correlated with 
Rheumatoid arthritis. Rheumatoid arthritis is an 
autoimmune disorder in which rheumatoid factor is 
found to be positive. Pain, inflammation or 
symmetrical swellings, stiffness in multiple joints 
particularly in morning and the onset may be with 
fever are major clinical features of Rheumatoid 
arthritis. This Rheumatoid arthritis involves other 
organs, including heart and muscles also. As the 
disease advances contractures are produced leading 
to deformity of affected joints like Swan neck 
deformity, Boutonniere deformity in joints of hand, 
flexion deformity in elbow, Hallux valgus deformity 
in foot etc.[3] Depending on the involvement of the 
joint, character of the pain and laboratory 
investigations, the final diagnosis was done. It is also 
a troublesome long persisting disorder having 
articular as well as extra articular signs and 
symptoms, yielding socio economic problems and 
unable to have self-care even. As per the data 
available 5% of the total population of the world is 
said to be affected with crippling disorder. It is 
estimated that females are affected three times that 
of the males usually manifests from 20-50 years of 
life.[4] 
According to Acharya Shodhana (bio-
purification), Shamana (pacification) and Nidana 
Parivarjanam are main modalities of treatment for 
any disease [5]. The prognosis of Aamvata is Krucha 
Sadhya (Difficult to Curable). But, there are some 
treatment modalities like Langhan (lightening), 
Swedana (sudation), Tikta (drugs having bitter taste), 
Katu (drugs having pungent taste), Virechana 
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(purgatives), Snehapana (intake of Sneha), Basti 
(Enema), Deepana (Appetisers), Pachana (digestive), 
Vatashamaka (pacifier of Vata) and Shothhara (anti-
inflammatory) which gives relief from the symptoms 
of Aamvata.[6] 
Presently, non-steroidal anti-inflammatory 
drugs (NSAIDs), DMARDs and steroids are the 
support of treatment in this condition; however, they 
have serious adverse effects and have limitations for 
a long-term therapy. Hence, there is a need for drugs 
having good efficacy with low toxicity profile in this 
debilitating disorder. Ayurveda has always given the 
best solutions for chronic disorders. In Bhavaprakash 
Samhita castor (Ricinis Communis) seed oil is 
mentioned as a best drug for Amavata.[7] Taking into 
above points of properties of drugs, in the present 
study as described in Chakradatta Castor oil 
medicated with Haritaki[8] which is also one of the 
Aampachana Yog by Acharya Charak and also acts as 
an Anulomana taken in one group and in another 
group Castor oil medicated with Sunthi[9] respectively 
for Matrabasti and Abhyantarpana was selected to 
assess their efficacy in the management of Amavata. 
Objectives of the study 
1. To assess the efficacy of Erandaharitaki as 
Abhyantarpana and Matrabasti in Aamvata. 
2. To assess the efficacy of Erandashunti as 
Abhyantarpana and Matrabasti in Aamvata. 
3. To compare efficacy of Erandaharitaki & 
Erandashunti in Aamvata. 
Materials and methods 
Patients suffering from Amavata were 
selected from OPD and IPD of Kayachikitsa 
Department of MGACH&RC, Salod (H), Wardha 
(Maharashtra). The cases were randomly selected 
irrespective of their age, sex, occupation, 
socioeconomic status and also, the one who was 
following the criteria of the diagnosis of Rheumatoid 
Arthritis according to the modern medical parameter 
and the clinical features of Amavata described in 
Madhava Nidana. These patients were randomly 
divided into two groups. Group I was treated with 
Erandaharitaki as Abhyantarpana and Matrabasti and 
group II was treated with Erandashunti as 
Abhyantarpana and Matrabasti. 
Statistical Analysis of Data 
The parameters of signs, symptoms were 
scored on the basis of standard method and was 
analysed statistically with ‘t’ test. 
Inclusion criteria 
 Age of patients between the age group of 20 to 65 
years in either sex, age, occupation, 
socioeconomic status presenting with clinical 
features of Aamvata such as – 
 Pain  
 Swelling at multiple joints 
 Lack of appetite and also clinical features of Aam.  
 The patients who fulfilled the criteria given by 
the American Rheumatism Association  
Exclusion criteria 
 Patients below 20 and above 65 years of the age  
 Patients with complications like deformity, 
severe pain & loss of functions.  
 Any other systemic and infectious disorders  
Diagnostic criteria 
American Rheumatism Association 1987 for 
the Diagnosis of the Disease was also followed for the 
confirmation of Rheumatoid arthritis, which is as 
follows: [10] 
1. Morning stiffness lasting for more than one hour 
2. Swelling of 3 or more specified joints 
3. Swelling of joints in hand and wrist 
4. Symmetrical swellings 
5. Presence of Rheumatoid nodules 
6. Rheumatoid factor positive 
7.Radiological changes such as particular 
osteoporosis, loss of articular cartilage or erosion. 
Criteria 2, 3, and 4 must be present for the duration 
of six weeks or more. 
Diagnosis of Rheumatoid arthritis is made with four 
or more criteria. 
Method of collection of data 
A special proforma were prepared with all 
points of General vital information about chief 
complaints, history of present and past illness, family 
history, personal history to get information about 
diet, appetite, bladder habits, bowel habits, allergies, 
addictions if any, along with treatment history was 
noted. Examinations like anthropometry, general 
physical examinations, systemic examinations and 
lab investigations are carried out as mentioned in 
Allied sciences. Accordingly, patients are selected and 
subjected to detailed clinical history and complete 
examinations. Selected patients are randomly placed 
under 2 groups as show in Table no.1 so in each 
group minimum 40 patients are included. 
Table 1: Methodology of interventions in both groups 
Trial Drug For Group A Trial Drug For Group B 
40 patients were treated with Erandaharitaki taila as 
Abhyantarpana – 15mland Matrabasti-60ml for 30 
consecutive days 
40 patients were treated with Erandashunti taila as 
Abhyantarpana-15ml and Matrabasti – 60ml for 30 
consecutive days. 
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Selection of Drug 
Erandataila is a well-known approved medicine for Amavata by Bhaishajyaratnavali[11] 
Drugs given in Table no. 2 
Table 2: Showing the contents of – Erandaharitaki taila 
S.no. Sanskrit name Botanical name Part used Quantity 
1 Erandataila Riccinus communis Linn.  Seed oil 4 parts 
2 Haritaki  Terminalia chebula Linn  Fruit  1 part 
Table 3: Showing the contents of – Erandashuntitaila 
S.no. Sanskrit name Botanical name Part used Quantity 
1 Erandataila Riccinus communis Linn.  Seed oil 4 parts 
2 Sunthi Zingiber officinale Roscoe.  Rhizome  1 part 
Method of Preparation  
For Abhyantarpana and Matrabasti of 80 
patients, the Taila was prepared in Dattatraya 
Rasashala of Mahatma Gandhi Ayurved College 
Hospital and Research Centre, Salod (H), Wardha.  
The Taila was prepared as per the Sneha 
Kalpana explained in Bhaisajya Ratnavali. For that 
1part of coarse powder of Shunti was taken and 
added it in 16 part of water, boiled the mixture until 
¼ part is remaining, after preparing of decoction to 
which 4 part of Eranda Taila and 1 part of Sunthi 
powder is added. The mixture was heated on low 
flame until the water gets evaporated. The same 




Sample size: 40 patients  
Sample type: Amavata 
Procedure: Abhyantarpana & Matrabasti with 
Erandaharitaki tailam 
Dose: Abhyantarpana - 15ml  
Matrabasti - 60ml  
Duration: 30 days  
Group B 
Sample size: 40 patients  
Sample type: Amavata 
Procedure: Abhyantarpana & Matrabasti with 
Erandashunti tailam 
Dose: Abhyantarpana - 15ml  
Matrabasti - 60ml  
Duration: 30 days  
Clinical Assessment 
 Assessment of symptoms were done and 
recorded on the15th day and 30th day after starting 
the treatment. Changes in the signs and symptoms 
were assessed by adopting suitable scoring method. 
Ethical clearance: This study was approved by 
Institutional Ethical Committee (IEC) of DMIMS vide 
letter no. DMIMS (DU)/IEC/2013-14/604; dated 
05.03.2014, before starting the clinical trial on 
clinically diagnosed patients of Amavata. 
Assessment Criteria  
Subjective parameters  
- Shula (Pain) 
- Sthambha (Stiffness) 
- Graha (Motion of joints) 
- Shotha (Swelling) 
- Vaivarnata (Discoloration) 
Objective parameters  
-RA titre  
-ESR 
Parameter with gradation  
Shula 
No pain : Grade 0 
Mild pain : Grade 1 
Moderate pain : Grade 2 
Severe pain : Grade 3 
Most excruciating pain : Grade 4 
Sthamba 
No stiffness or stiffness lasting for 5 
minutes  
: Grade 0 
Stiffness lasting for 6 minutes to 30 
minutes  
: Grade 1 
Stiffness lasting for 35 minutes to 1 hour  : Grade 2 
Stiffness lasting for 1 ½ hour to 2 hours : Grade 3 
Stiffness lasting for more than 2 hours : Grade 4 
Graha 
Normal joint motion  : Grade 0 
About 25-49% loss of motion  : Grade 1 
About 50% loss of motion  : Grade 2 
About 75% loss of motion  : Grade 3 
100% loss of motion or complete 
ankyloses of the joint  
: Grade 4 
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Shotha 
No Swelling : Grade 0 
Joint swelling which may not be 
apparent on casual inspection, but 








Joint swelling obvious even on casual 
observation 
: Grade 2 
Markedly abnormal swelling : Grade 3 
Joint swelling to a maximally abnormal 
degree 
: Grade 4 
Vaivarnata 
Absent  : Grade 0 
Mild  : Grade 1 
Moderate  : Grade 2 
Marked  : Grade 3 
Severe  : Grade 4 
Observation 
Maximum patients registered in the age 
group of 41-50 years of age 56.67%. Most of the 
patients were female 63% as compared to male 
patients 37%.  
Out of 80 patients, 96.67% were Hindus, and 
3.33% were Muslims. 93.33% patients were married. 
6.67% were unmarried. 6.67% patients were 
uneducated, remaining 93.33% were distributed in 
different level like primary 26.67%, secondary 30%, 
graduate 23.33% and post graduate 13.33%. Majority 
of the patients 43.33% in this series were belonging 
to middle economic status, while 23.33% were 
belonging to upper middle class.  
Maximum number of patients 60% were 
possessing Vata-Kapha Prakruti, 23.33% Vata-Pitta 
and 16.67% patients were of Pitta-Kapha Prakruti. 
Out of all the patients, 76.67% were of Manda Agni 
and 23.33% Visama Agni. Maximum patients 76.67% 
had Madhyama Koshtha, which was followed by 
Krura Kostha were13.33% and Mrudu Kostha were 
10%. 
Table 4: Statistical analysis on overall Subjective parameters in Group A 






d.f t.value Remarks Efficacy 
% 
1 Shula 2.93± 0.15 AT1 1.6±0.19 14 10.58 H.S. 45.45 
AT2 0.67±0.16 14 12.47 H.S. 77.27 
2 Stambha 2.33±0.13 AT1 1.33±0.16 14 10.25 H.S. 42.86 
AT2 0.47±0.13 14 20.55 H.S. 80 
3 Graha 1.6±0.13 AT1 0.87±0.17 14 6.21 H.S. 45.83 
AT2 0.33±0.13 14 10.72 H.S. 79.17 
4 Shotha 2.27±0.15 AT1 1.33±0.13 14 7.90 H.S. 41.18 
AT2 0.47±0.14 14 12.44 H.S. 79.41 
5 Vivarnata 2.07±0.15 AT1 1.47±0.19 14 4.58 H.S. 29.03 
AT2 0.47±0.13 14 9.80 H.S. 77.42 
Table 5: Statistical analysis on overall Subjective parameters in Group B 










1 Shula 2.93± 0.15 AT1 2.0±0.20 14 7.90 H.S. 31.82 
AT2 1.33±0.25 14 9.80 H.S. 54.55 
2 Stambha 2.20±0.15 AT1 1.47±0.19 14 6.21 H.S. 33.33 
AT2 1.07±0.23 14 6.85 H.S. 51.52 
3 Graha 1.6±0.13 AT1 1.23±0.15 14 2.65 S. 20.83 
AT2 0.87±0.19 14 4.78 H.S. 45.83 
4 Shotha 2.47±0.13 AT1 1.67±0.16 14 7.48 H.S. 32.43 
AT2 1.07±0.24 14 8.57 H.S. 56.76 
5 Vivarnata 2.07±0.17 AT1 1.60±0.16 14 3.06 H.S. 20 
AT2 1.13±0.24 14 5.25 H.S. 43.33 
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Table 6: Statistical analysis on overall Objective parameters in Group A 






d.f t.value Remarks Efficacy% 
1 ESR 52.53±4.39 AT1 45.87±4.38 14 6.52 H.S 12.69 
AT2 39.87±3.62 14 6.59 H.S 24.11 
2 RA Titre 298.67±14.14 AT1 284.53±14.01 14 10.48 H.S 4.73 
AT2 271.13±13.85 14 10.79 H.S 9.22 
Table 7: Statistical analysis on overall Objective parameters in Group B 






d.f t.value Remarks Efficacy% 
1 ESR 53.80±4.86 AT1 45.33±4.69 14 6.52 H.S 15.74 
AT2 36.00±3.56 14 6.59 H.S 33.09 
2 RA Titre 305.13±16.89 AT1 289.53±15.94 14 10.48 H.S 5.11 
AT2 268.93±15.85 14 11.29 H.S 11.86 
RESULTS 
Effect on Sandhishula 
Relief in Sandhishula was observed 77.27% 
among the patients of Group-A while the patients of 
Group-B showed 54.55% improvement. Both the 
results were statistically highly significant (P < 0.01). 
Effect on Stambha 
80% relief was observed in Sandhistambha 
among the patients of Group-A, while the patients of 
Group-B showed 51.52% improvement. The relief 
was statistically highly significant (P<0.01) in both 
the groups. 
Effect on Graha 
In both the groups, highly significant results 
were recorded in Graha of the joints. However, the 
percentage was found to be higher in Group-A 
79.17% compared to Group-B 45.83%. Statistically 
both were highly significant (P<0.01). 
Effect on Sandhishotha 
In both the Groups highly significant (P<0.01) 
improvement was recorded in inflammation. Group-
A showed 79.41 % relief and Group B showed 56.76 
% relief. 
Effect on Vivarnata  
The effect on Vivarnata was observed as 
77.42% in group-A patients while it recorded as 
43.33% in group-B. The improvement was 
statistically highly significant (P<0.01).  
Effect on ESR 
In Group A, change in ESR value was 33.09% 
while in Group B it was 24.11% in E.S.R. value. The 
results found in both groups were statistically highly 
significant (P<0.01).  
 
 
Effect on RA Titre 
In Group A change was 11.86% while in 
Group B it was 9.22%. The results found in both 
groups were statistically highly significant (P<0.01). 
DISCUSSION 
According to Acharya Madhavkara, Aam 
which is formed due to Consumption of food 
substance without following rules and regulations of 
diet described in Astaviddha Ahara Vidhi 
Visesayatana. This Aam disturbs Agni especially 
Jatharagni. Due to this the food is not properly 
digested and form immature Ahar rasa in the 
Amasaya and this undergoes fermentation and 
disintegration manifests ‘Ama’. Then it absorbed in 
the circulation along with aggravated and vitiated 
Vata, Pitta and Kapha and gets accumulated all over 
the body specially to the Kaphasthanas mainly 
Amasaya and Sandhi leads to restriction in 
movement of joint, produces pain, tenderness and 
swelling in affected site or joint and Stabdhata in 
body, this condition is called Aamvata which is 
correlated with Rheumatoid Arthritis.[12] 
In the terminologies of Ayurveda 
Shodhana (bio-purification), Shamana (pacification) 
and Nidana Parivarjanam are main modalities of 
treatment for any disease. In Shamana therapy the 
drug which is having Katu (pungent), Tikta (bitter) 
Rasa and which acts as a Deepana (appetizer) and 
Pachana (Digestive) are recommended in Aamvata. 
This good quality of drug does Amapachana, which 
helps in relieving Shotha & Shoola. In Shodhana 
therapy Acharya Chakradatta recommends Basti 
Chikitsa and Virechana in Aamvata.[13] 
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In present study the Erandataila is used for 
Basti and oral administration which cause Pachana 
of Aam present in Antra and Rasa by their Tikta, 
Katu Anurasa and Ushna Verya. Because of Snighdha 
and Ushnaguna, oil pacifies Vyanvayu. Hence it is 
very useful in Amavata.[14] In Group A this 
Erandataila is given with Haritaki which Kaphaghna 
is being Katu, Tikta, Kashaya, Laghu and Rooksha 
and Vataghna due to Amla and Madhura rasa and 
Ushna Veerya. This also acts as a Shootha hara and 
Shoolahara. Due to its Tikta rasa and Ushnaveerya it 
is Depana and Pachana, and Anulomana due to its 
Kashya rasa. It is also use to digest Sama Dosha and 
expels in the Nirama form. It eliminates the 
Strotorodha and thus by clearing the passage, 
carries out nourishment of all Dhatu specially Mansa 
Dhatu by removing obstruction, refreshes the body 
and increases the strength and it also stimulate the 
Dhatvagni[15] and In Group B Eranda Taila is given 
with Sunthi which is Kaphaghna being Katu in Rasa, 
Laghu and Snigdha in Guna and Ushna in Veeryaas 
well as Vataghna and Amapachana.[16] This Eranda 
and Sunthi together help to pacify the Sandhishotha 
and Shoola. 
Probable mode of action of Matra Basti 
Basti has been mentioned by Acharya 
Charak to be the important therapy to manage Vata 
Dosha and it is called as Ardha Chikitsa. Basti Karma 
acts on various systems like GIT, enteric nervous 
system and autonomic nervous system of body 
besides exerting local action.[17]Ingredients of Matra 
Basti are Eranda Taila with Haritaki in group A and 
Eranda Taila with Sunthi in group B was given. As a 
whole, the qualities of Matra Basti can be 
considered as Laghu, Ruksha, Ushna, Snigdha. The 
drugs which are used have Vata, Kapha 
Shamaka and Aampachana action. Owing to these 
properties treatment with the Basti has provided 
significant improvement in sign and symptom of 
disease. The Guna of Basti helps in overcoming 
the Srotodushti resulting due to Sanga, thus help in 
breaking down the pathogenesis of disease. 
CONCLUSION 
The present study shows the efficacy of 
Ayurveda intervention including both Shodhan and 
Shamana applied following the treatment strategy as 
explained in classical text books in a case of Aamvata. 
In nut shell the drugs have helped in eliminates the 
Aam regulates the direction of activity of Apana Vayu 
(Anulomana) and providing a strength to muscles of 
body and joints. Such similar treatment protocol can 
be followed in the cases of Aamvata disease. It is 
found that Both the Groups show highly significant 
results but improvement was better in Group A were 
Abhyantarpana & Matrabasti with Erandaharitaki 
Tailam in comparison to Group B Abhyantarpana & 
Matrabasti with Erandashunti Tailam. Matra Basti & 
Abhyantrapana has provided better relief in most of 
the Cardinal, General and associated features of the 
disease at significant level. Comparatively Eranda-
haritaki Taila Matra Basti and Abyantrapana were 
found well tolerable in all age groups with minimum 
complications. 
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